CRON Stock Overview
Operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Risk Analysis
No risks detected for CRON from our risk checks.
Cronos Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.79 |
| 52 Week High | CA$4.28 |
| 52 Week Low | CA$2.48 |
| Beta | 1.01 |
| 11 Month Change | -6.06% |
| 3 Month Change | -10.86% |
| 1 Year Change | 0.72% |
| 33 Year Change | -54.34% |
| 5 Year Change | -69.51% |
| Change since IPO | 236.14% |
Recent News & Updates
Recent updates
We're Interested To See How Cronos Group (TSE:CRON) Uses Its Cash Hoard To Grow
May 31
Cronos Group Inc.'s (TSE:CRON) P/S Is Still On The Mark Following 29% Share Price Bounce
Apr 01We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth
Mar 02Revenues Tell The Story For Cronos Group Inc. (TSE:CRON)
Feb 02Companies Like Cronos Group (TSE:CRON) Are In A Position To Invest In Growth
Nov 09We're Hopeful That Cronos Group (TSE:CRON) Will Use Its Cash Wisely
Jul 17Cronos Group Inc.'s (TSE:CRON) Earnings Haven't Escaped The Attention Of Investors
Jun 20We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth
Feb 09A Look At The Intrinsic Value Of Cronos Group Inc. (TSE:CRON)
Oct 12We're Not Very Worried About Cronos Group's (TSE:CRON) Cash Burn Rate
Sep 10Cronos Group Inc. (TSE:CRON) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 12We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth
May 19Is Cronos Group Inc. (TSE:CRON) Trading At A 47% Discount?
Jul 29An Intrinsic Calculation For Cronos Group Inc. (TSE:CRON) Suggests It's 29% Undervalued
Apr 08Have Insiders Sold Cronos Group Inc. (TSE:CRON) Shares Recently?
Mar 04Shareholder Returns
| CRON | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -7.9% | -6.1% | 0.7% |
| 1Y | 0.7% | -22.3% | 21.7% |
Return vs Industry: CRON exceeded the Canadian Pharmaceuticals industry which returned -22.3% over the past year.
Return vs Market: CRON underperformed the Canadian Market which returned 21.7% over the past year.
Price Volatility
| CRON volatility | |
|---|---|
| CRON Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 11.5% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: CRON has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: CRON's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 356 | Mike Gorenstein | www.thecronosgroup.com |
Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
Cronos Group Inc. Fundamentals Summary
| CRON fundamental statistics | |
|---|---|
| Market cap | CA$1.08b |
| Earnings (TTM) | -CA$66.50m |
| Revenue (TTM) | CA$155.51m |
6.9x
P/S Ratio-16.0x
P/E RatioIs CRON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRON income statement (TTM) | |
|---|---|
| Revenue | US$111.23m |
| Cost of Revenue | US$87.81m |
| Gross Profit | US$23.42m |
| Other Expenses | US$70.98m |
| Earnings | -US$47.56m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 21.06% |
| Net Profit Margin | -42.76% |
| Debt/Equity Ratio | 0% |
How did CRON perform over the long term?
See historical performance and comparison